March 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.
March 2026 in “SHILAP Revista de lepidopterología” In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy, suggesting a rare association between the drug and these immune-mediated skin conditions, highlighting the potential benefit of early intervention with baricitinib.
April 2020 in “Rheumatology” This case report describes successful and sustained treatment of alopecia universalis with rituximab in a patient also diagnosed with dermatomyositis, suggesting a potential role for B cells in its pathogenesis.
January 2026 in “SKIN The Journal of Cutaneous Medicine” Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
7 citations
,
September 2021 in “Dermatologic Therapy” This review summarizes treatments for scalp involvement in dermatomyositis and suggests that therapies like low-dose naltrexone and platelet-rich plasma may warrant further investigation, although evidence remains limited.
